Ian has more than 20 years of experience in the pharmaceutical industry, gained through senior positions in sales, marketing, business development & licensing in both multinational companies and biotech. Through Atebion BDS, he assists spin-outs, BioTech and Major Pharmaceutical Companies in their strategic investment decisions.
He has Non-Executive Director positions in early-stage BioTech companies focusing on BioAnalytic and Antibody Drug Conjugation platforms, is a member of Epiphany Capital and is a Strategic Adviser for BioTech Companies in Spain, UK and Singapore
With his extensive experience and knowledge in clinical practice and commercialisation of medicine, Ian works to shape and develop clients through critical inflection points, taking them to a successful fundraising. He is a consultant to research institutions, emerging biotechs, pharmaceutical companies and VC Groups for business development, asset valuation & commercialisation strategies.
Before setting up Atebion, Ian was Portfolio & Evaluations Director for AstraZeneca, responsible for BD&L and techno-commercial asset evaluation of in-house and externalisation opportunities on behalf of the ex-US Business. He has a PhD in clinical chemistry.
Tim Dempsey assists Atebion BDS in investor-related projects, whether this relates to defining investor strategy, brokering investor / VC meetings for Investment Rounds, providing company valuations or for the general support of investment decisions.
Tim has been involved with funding spin-outs and early stage companies since leaving university in 2006, and established boutique corporate finance house Epiphany Capital in 2010. Epiphany advises high growth companies in the healthcare and technology sectors, raising venture capital from institutional investors. Alongside Epiphany, Tim sits on advisory panels for GSK’s Stevenage Bioscience Catalyst and the University of Manchester Incubation Company. Outside of work he is trustee of two charities and conductor of a choir. Tim holds a BA(Hons) in Politics, Philosophy and Economics from the University of Manchester.
Dave Simpson PhD has spent over 15 years’ in the biotherapeutics industry developing and commercialising biologics with Cobra Biologics, Eden Biodesign and Actavis (now Allergan) and is currently the CEO of Glythera Ltd, an Antibody Drug Conjugate development company.
Dave supported IP Group from October 2011 to develop Glythera's business strategy and fundraising activities. Having co-founded Glythera as Chief Operating officer in March 2012, Dave was appointed CEO in February 2014 and continues to lead the strategic direction and growth of the business.
After training as a molecular biologist specialising in the epigenetic and genetic control of cancer, Dave joined Cobra Biologics (now Cobra Biomanufacturing), where he successfully developed the UCOE expression system (subsequently acquired by Millipore Inc.). Dave joined Eden Biodesign as a founding member of the management team and, having headed Process Development and delivered multiple product classes into the clinic, moved to lead the development and commercialisation of Actavis’s biologics programmes after Eden’s successful acquisition in 2010.
Through his commercial and technical background, Dave continues to support a number of UK Universities, biotech companies and major US corporations in developing their technical, product and commercialisation strategies.